greeksoup/ stocks
Stocks / India / DRREDDY / Q4 FY2024

Dr. Reddy's Laboratories Ltd. Q4 FY2024 results: revenue ₹7,114 crore, up 12.6% on the year

Dr. Reddy's Laboratories Ltd. (DRREDDY) reported consolidated revenue from operations of ₹7,114 crore for Q4 FY2024, the quarter ended 31 March 2024, up 12.6% on the same quarter a year earlier. Profit after tax was ₹1,310 crore, up 36.4% on the year, and earnings per share ₹78.66. The figures are the company's own, from the audited results it filed with NSE on 7 May 2024.

Revenue from operations₹7,114 croreup 12.6%
Profit after tax₹1,310 croreup 36.4%
EPS₹78.66
QuarterQ4 FY2024ended 31 March 2024

The quarter, against the one before and a year earlier

LineQ4 FY2024Q3 FY2024A year earlierChange on the year
Revenue from operations7,1147,237n/an/a
Other income198216n/an/a
Total income7,3117,453n/an/a
Cost of materials consumed1,0961,141n/an/a
Purchases of stock-in-trade1,1761,208n/an/a
Changes in inventories-180-174n/an/a
Employee benefit expense1,2841,276n/an/a
Finance costs5939n/an/a
Depreciation, depletion and amortisation368374n/an/a
Other expenses1,9071,761n/an/a
Total expenses5,7105,627n/an/a
Profit before exceptional items and tax1,6021,826n/an/a
Exceptional items00n/an/a
Profit before tax1,6021,826n/an/a
Current tax282354n/an/a
Deferred tax1394n/an/a
Total tax295448n/an/a
Profit after tax1,3101,381n/an/a
Attributable to owners of the parent00n/an/a
Other comprehensive income-5699n/an/a
Total comprehensive income1,2541,480n/an/a
EPS, basic₹78.66₹82.94n/an/a
EPS, diluted₹78.53₹82.81n/an/a

₹ crore except per share.

Quarterly results, the last 12 quarters

Q2 FY2024Q3 FY2024Q4 FY2024Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025Q1 FY2026Q2 FY2026Q3 FY2026Q4 FY2026Q1 FY2027
Sales6,9037,2377,1147,6968,0388,3818,5288,5728,8288,7537,5468,100
Expenses5,3055,6275,7106,0076,4346,6617,0516,9587,4147,4817,8277,902
Operating profit2,0082,0231,8312,1302,0762,2731,9982,1742,0101,887382860
OPM %29%28%26%28%26%27%23%25%23%22%5%11%
Other income315216198187308150522290324269475355
Interest35395960768266839194106126
Depreciation376374368381397471455476505521557537
Exceptional items000000000000
Profit before tax1,9121,8261,6021,8771,9111,8702,0001,9051,7381,541195552
Tax %23%25%18%26%30%25%21%26%23%23%-11%21%
Net profit1,4821,3811,3101,3921,3421,4041,5871,4101,3371,190221436
EPS in ₹₹89.09₹82.94₹78.66₹83.61₹15.08₹16.97₹19.12₹17.04₹16.18₹14.53₹2.65₹5.33
FilingNSENSENSENSENSENSEFilingFilingFilingFilingFilingFiling

₹ crore except per share, consolidated, as filed with the exchange. Operating profit is sales less the expenses other than interest and depreciation, OPM is that over sales, and tax % is tax over profit before tax: arithmetic on the filed lines; everything else is as filed. Quarters before December 2024 are from the exchange's earlier results feed, which carries the filed lines without the filing itself; the column links to the exchange's page for the company. EPS is as filed for each quarter. A split or a bonus issue changes the share count, so quarters before it are on the old count.

Source

Audited consolidated results for the quarter ended 31 March 2024, filed with NSE on 7 May 2024: the result statement. All of Dr. Reddy's Laboratories Ltd.'s results: NSE company page.

The same record on your computer

GreekSoup is also a free program for your own computer. It reads these same filings for the names you follow, refreshed as they land, with no account. One pasted line installs it.

Install